Immucell Stock Net Income
| ICCC Stock | USD 5.44 0.04 0.74% |
ImmuCell fundamentals help investors to digest information that contributes to ImmuCell's financial success or failures. It also enables traders to predict the movement of ImmuCell Stock. The fundamental analysis module provides a way to measure ImmuCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuCell stock.
ImmuCell |
ImmuCell Company Net Income Analysis
ImmuCell's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current ImmuCell Net Income | (5.77 M) |
Most of ImmuCell's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuCell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, ImmuCell reported net income of (5.77 Million). This is 101.69% lower than that of the Biotechnology sector and 108.24% lower than that of the Health Care industry. The net income for all United States stocks is 101.01% higher than that of the company.
ImmuCell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuCell's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics of similar companies.ImmuCell is currently under evaluation in net income category among its peers.
ImmuCell Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0487 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 59.85 M | ||||
| Shares Outstanding | 8.91 M | ||||
| Shares Owned By Insiders | 39.52 % | ||||
| Shares Owned By Institutions | 14.51 % | ||||
| Number Of Shares Shorted | 15.75 K | ||||
| Price To Earning | 195.00 X | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 2.09 X | ||||
| Revenue | 17.47 M | ||||
| Gross Profit | 7.65 B | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (5.77 M) | ||||
| Cash And Equivalents | 11.04 M | ||||
| Cash Per Share | 1.43 X | ||||
| Total Debt | 16.69 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 6.91 X | ||||
| Book Value Per Share | 3.23 X | ||||
| Cash Flow From Operations | (4.67 M) | ||||
| Short Ratio | 0.23 X | ||||
| Earnings Per Share | (0.49) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 32.08 M | ||||
| Total Asset | 43.81 M | ||||
| Retained Earnings | (12.01 M) | ||||
| Working Capital | 10.92 M | ||||
| Current Asset | 4.49 M | ||||
| Current Liabilities | 258.78 K | ||||
| Net Asset | 43.81 M |
About ImmuCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out ImmuCell Piotroski F Score and ImmuCell Altman Z Score analysis. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.